New agents in metastatic prostate cancer

Area of Science:

• Oncology
• Urology
• Pharmacology

Background:

• Metastatic castration-resistant prostate cancer (CRPC) presents significant treatment challenges.
• Recent discoveries in molecular mechanisms have identified new therapeutic targets.
• Several novel agents have emerged for CRPC treatment.

Purpose of the Study:

• To summarize phase III clinical trial data for recently approved and investigational agents in metastatic CRPC.
• To highlight promising single-agent therapies currently in phase III studies.
• To discuss unanswered questions and propose a schema for the evolving use of these therapies.

Main Methods:

• Review of published phase III clinical trial data for approved and investigational agents in metastatic CRPC.
• Analysis of efficacy and safety profiles of these agents.
• Synthesis of current regulatory approvals and projected treatment evolution.

Main Results:

• Five agents (cabazitaxel, abiraterone, sipuleucel-T, denosumab, enzalutamide) have been approved for metastatic CRPC within the past two years.
• Alpharadin demonstrated overall survival benefit in a phase III trial.
• PROSTVAC-VF, ipilimumab, and cabozantinib are among other promising therapies in phase III studies.

Conclusions:

• While curative options for metastatic CRPC are still lacking, recent therapeutic advancements offer hope.
• Optimization of current and emerging treatment strategies is crucial for reducing disease-related morbidity and mortality.
• Ongoing research and evolving data will shape future treatment paradigms for metastatic CRPC.